We are excited to share the publication of the first-in-human clinical studyof COVAC-2, a recombinant protein subunit vaccine against COVID-19 formulated with Sepivac SWE™, an oil-in-water adjuvant co-developed by VFI and Seppic. Led by our long-standing partner Vaccine and Infectious Disease Organization (VIDO), the study confirms that the Sepivac SWE™-adjuvanted vaccine is safe and induces robust neutralizing antibody responses across age groups.
Read the article.